Publication: Association between IL-18 gene polymorphisms and biopsy-proven giant cell
Loading...
Identifiers
Date
2010-03
Authors
Palomino-Morales, Rogelio J
Vazquez-Rodriguez, Tomas R
Torres, Orlando
Morado, Inmaculada C
Castañeda, Santos
Miranda-Filloy, Jose A
Callejas-Rubio, Jose L
Fernandez-Gutierrez, Benjamin
Gonzalez-Gay, Miguel A
Martin, Javier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
Abstract
INTRODUCCIÓN: El objetivo fue investigar la posible implicación de los polimorfismos de promotor del gen IL18 en la susceptibilidad a la arteritis de células gigantes (ACG). MÉTODOS: En total, 212 pacientes con diagnóstico de ACG probada por biopsia fueron incluidos en este estudio. ADN de los pacientes y controles pareados se obtuvo a partir de sangre periférica. Las muestras fueron genotipo para la IL18-137 G> C (rs187238), la IL18-607 C> A (rs1946518), y la T IL18-1297> C (rs360719) polimorfismos del gen con la reacción en cadena de polimerasa, utilizando un prediseñado alelo TaqMan discriminación ensayo. RESULTADOS: No se encontró asociación significativa entre la IL18-137 G> polimorfismo C y GCA ha sido encontrado. Sin embargo, la IL18 -607 alelo A fue significativamente mayor en pacientes con ACG en comparación con los controles (47,8% versus 40,9% en pacientes y controles respectivamente, p = 0,02, OR, 1,32, IC 95%: 1,04 a 1,69). Fue debido a un aumento de la frecuencia de homocigosis para la IL18 -607 A / A en el genotipo de los pacientes con ACG (20,4%) en comparación con los controles (13,4%) (IL18 -607 A / A en comparación con IL18 -607 A / C más IL18 - 607 C / C genotipos: P = 0,04, o bien, 1.59, IC 95%, 1.02 a 2.46). Además, la C-1297 alelo IL18 fue significativamente mayor en pacientes con ACG (30,7%) en comparación con los controles (23,0%) (p = 0,003, OR, 1,48, IC 95%: 1,13 a 1,95). En este sentido, una mayor susceptibilidad a la ACG se observó en los individuos portadores de los IL18-1297 C / C o los IL18-1297 C / T genotipos en comparación con los portadores del IL18-1297 genotipo T / T (IL18-1297 C / C más IL18-1297 T / C en función de IL18-1297 genotipo T / T en pacientes con ACG en comparación con los controles: p = 0,005, OR, 1,61, IC 95% 1,15 a 2,25). También se encontró un efecto aditivo de los IL18 -1297 y -607 polimorfismos de TLR4 con el polimorfismo Asp299Gly. El OR para la ACG fue de 1,95 para las combinaciones de genotipos con uno o dos alelos de riesgo, mientras que los portadores de tres o más alelos de riesgo tienen un OR de 3.7. CONCLUSIONES: Nuestros resultados muestran por primera vez una implicación de IL18-promotor del gen de los polimorfismos en la susceptibilidad a la demostrada por biopsia ACG. Además, un efecto aditivo entre los asociados IL18 y TLR4 variantes genéticas se observó.
INTRODUCTION: The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms in the susceptibility to giant-cell arteritis GCA). METHODS: In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C (rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase chain reaction, by using a predesigned TaqMan allele discrimination assay. RESULTS: No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18 -607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95). In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297 C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was 1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an OR of 3.7. CONCLUSIONS: Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic variants was observed.
INTRODUCTION: The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms in the susceptibility to giant-cell arteritis GCA). METHODS: In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C (rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase chain reaction, by using a predesigned TaqMan allele discrimination assay. RESULTS: No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18 -607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95). In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297 C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was 1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an OR of 3.7. CONCLUSIONS: Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic variants was observed.
Description
MeSH Terms
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Biopsy
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype::Genetic Predisposition to Disease
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype
Medical Subject Headings::Diseases::Immune System Diseases::Autoimmune Diseases::Autoimmune Diseases of the Nervous System::Vasculitis, Central Nervous System::Giant Cell Arteritis
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-18
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Linkage::Linkage Disequilibrium
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Prednisolone::Methylprednisolone
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors::Toll-Like Receptor 4
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype::Genetic Predisposition to Disease
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genotype
Medical Subject Headings::Diseases::Immune System Diseases::Autoimmune Diseases::Autoimmune Diseases of the Nervous System::Vasculitis, Central Nervous System::Giant Cell Arteritis
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-18
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Linkage::Linkage Disequilibrium
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Prednisolone::Methylprednisolone
Medical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors::Toll-Like Receptor 4
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
DeCS Terms
CIE Terms
Keywords
Biopsia, Quimioterapia Combinada, Predisposición Genética a la Enfermedad, Genotipo, Arteritis de Células Gigantes, Interleucina-18, Desequilibrio de Ligamiento, Metilprednisolona, Polimorfismo Genético, Prednisona, Receptor Toll-Like 4, Humanos
Citation
Palomino-Morales RJ, Vazquez-Rodriguez TR, Torres O, Morado IC, Castañeda S, Miranda-Filloy JA, et al. Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Res Ther. 2010;12(2):R51.